Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-23T17:34:29.040Z Has data issue: false hasContentIssue false

Haloperidol Decanoate v. Fluphenazine Decanoate as Maintenance Therapy in Chronic Schizophrenic In-patients

Published online by Cambridge University Press:  02 January 2018

J. P. McKane
Affiliation:
Crichton Royal Hospital
A. D. T. Robinson
Affiliation:
Crichton Royal Hospital
D. H. Wiles
Affiliation:
Crichton Royal Hospital
R. G. McCreadie*
Affiliation:
Crichton Royal Hospital
G. S. Stirling
Affiliation:
Crichton Royal Hospital
*
Crichton Royal Hospital, Dumfries, Dumfries DG1 4TG

Extract

In a double-blind study of 38 chronic schizophrenic in-patients, haloperidol decanoate was compared with fluphenazine decanoate as maintenance therapy over 60 weeks. Both drugs were given by injection at 4-week intervals. Haloperidol and fluphenazine were assumed to be equipotent; the mean starting dose of the former was 127 mg and of the latter 106 mg. The number of withdrawals over 60 weeks was similar in both groups but relapses, strictly defined, were significantly more frequent in the haloperidol group. When patients were switched to haloperidol, Parkinsonism diminished more quickly than in the fluphenazine group, but after 60 weeks there was no difference in severity in the two drug groups. The higher relapse rate and the quicker reduction in Parkinsonism in the haloperidol group might be due to a misjudgement in equivalent doses of the two drugs. Plasma haloperidol steady state levels were reached in most patients by 8–12 weeks. Plasma neuroleptic and prolactin levels, week-by-week systemic drug availability and Parkinsonism showed less variation between injections with haloperidol than with fluphenazine.

Type
Papers
Copyright
Copyright © Royal College of Psychiatrists, 1987 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ayd, F. J. (1980) Haloperidol Update 1958–1980. Baltimore: Ayd Medical Communications.Google Scholar
Bechelli, L. P. C., Iecco, M. C, Acioli, A. & Pontes, M. C. (1985) A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public out-patient clinic. Current Therapeutic Research, 37, 662671.Google Scholar
British National Formulary (1984) London: British Medical Association and the Pharmaceutical Society of Great Britain.Google Scholar
Chouinard, G., Annable, L., Campbell, W., Boisvert, D. & Bradwejn, J. (1984) A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Psychopharmacology Bulletin, 20, 108109.Google ScholarPubMed
Davis, J. M. (1976) Comparative doses and costs of anti-psychotic medication. Archives of General Psychiatry, 33, 858861.CrossRefGoogle Scholar
Deberdt, R., Elens, P., Berghmans, W., Heykants, J., Woestenborghs, R., Driesens, F., Reyntjens, A. & Van Wungaarden, I. (1980) Intra-muscular haloperidol decanoate for neuroleptic maintenance therapy: efficacy, dosage schedule and plasma levels. Acta Psychiatrica Scandinavica, 62, 356363.CrossRefGoogle Scholar
Feighner, J. P., Robins, E., Guze, S., Woodruff, R. A., Winokur, G. & Munoz, R. (1972) Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry, 26, 5762.CrossRefGoogle ScholarPubMed
Kissling, W., Moller, H. J., Walter, K., Wittman, B., Krueger, R. & Trenk, D. (1985) Double-blind comparison of haloperidol decanoate and fluphenazine decanoate: effectiveness, side effects, dosage and serum levels during a six month's treatment for relapse prevention. Pharmacopsychiatry, 18, 240245.CrossRefGoogle Scholar
Krawiecka, M., Goldberg, D. & Vaughan, M. (1977) A standardised psychiatric assessment scale for rating psychotic patients. Acta Psychiatrica Scandinavica, 55, 299308.CrossRefGoogle ScholarPubMed
Leff, J. & Vaughn, C. (1980) The interaction of life events and relatives expressed emotion in schizophrenia and depressive neurosis. British Journal of Psychiatry, 136, 146153.CrossRefGoogle ScholarPubMed
Reyntjens, A. J. M., Heykants, J. J. P., Woestenborghs, R., Gelders, Y. G. & Aerts, T. J. L. (1982) Pharmacokinetics of haloperidol decanoate: a two year follow up. International Pharmacopsychiatry, 17, 238246.CrossRefGoogle Scholar
Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, suppl. 212, 1119.CrossRefGoogle ScholarPubMed
Suy, E., Woestenborghs, C. & Heykants, J. (1982) Bioavailability and clinical effects of two different concentrations of haloperidol decanoate. Current Therapeutic Research, 31, 982991.Google Scholar
U.S. Department Of Health, Education And Welfare (1976) Abnormal Involuntary Movements Scale (AIMS). In ECDEU Assessment Manual (ed. Guy, W.). Rockville, Maryland: US Department of Health, Education and Welfare.CrossRefGoogle Scholar
Wiles, D. H. & Franklin, M. (1978) Radioimmunoassay for fluphenazine in human plasma. British Journal of Clinical Pharmacology, 5, 265268.CrossRefGoogle ScholarPubMed
Wing, J. K. (1961) A simple and reliable subclassification of schizophrenia. Journal of Mental Science, 107, 862875.CrossRefGoogle ScholarPubMed
Wistedt, B., Persson, T. & Hellbom, E. (1984) A clinical double blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research, 35, 804814.Google Scholar
Wyatt, R. J. & Torgow, J. S. (1976) A comparison of equivalent clinical potencies of neuroleptics as used to treat schizophrenia and affective disorders. Journal of Psychiatric Research, 13, 9198.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.